1. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients
    Xin Zhao et al, 2014, Tumor Biology CrossRef
  2. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
    R. Mlak et al, 2016, Clinical and Translational Oncology CrossRef
  3. Correlation Between TS, MTHFR, and ERCC1 Gene Polymorphisms and the Efficacy of Platinum in Combination With Pemetrexed First-Line Chemotherapy in Mesothelioma Patients
    Tomasz Powrózek et al, 2014, Clinical Lung Cancer CrossRef
  4. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness
    Qingxiang Lin et al, 2024, Drug Resistance Updates CrossRef
  5. A novel antibody-based approach to detect the functional ERCC1-202 isoform
    Mei-Shiue Kuo et al, 2018, DNA Repair CrossRef
  6. Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems
    Yi Xiong et al, 2017, Medical Oncology CrossRef
  7. A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis
    Yali Han et al, 2016, Disease Markers CrossRef
  8. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis
    Li-Ming Tan et al, 2017, Scientific Reports CrossRef
  9. Molecular Markers for Treatment Response and Toxicity of Gemcitabine
    L.V.K.S. Bhaskar et al, 2019, Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy CrossRef
  10. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer
    Shao-jun Huang et al, 2014, Tumor Biology CrossRef
  11. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1
    Gerhard Hamilton et al, 2018, Expert Opinion on Drug Metabolism & Toxicology CrossRef
  12. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer
    Qingxiang Lin et al, 2022, Molecular & Cellular Proteomics CrossRef
  13. Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta‐Analysis
    Hilary Sito et al, 2024, British Journal of Biomedical Science CrossRef
  14. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
    Paweł Krawczyk et al, 2014, Journal of Cancer Research and Clinical Oncology CrossRef
  15. The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer
    Joshua T. Burgess et al, 2020, Frontiers in Oncology CrossRef
  16. Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer
    Hilary Sito et al, 2024, Molecular Biology Reports CrossRef